Specifically, dysregulation of GSK-3β activity has been reported in neurological diseases such as bipolar disorder (BD) [6,7,8] and in neurodegenerative disorders such as Alzheimer’s disease (AD) [9,10], Parkinson’s disease (PD) [11,12,13] and Huntington’s disease (HD) [14,15,16]. The gene discussed is GSK3B; the disease is Alzheimer disease.